Prot #DB-1303-O-3002: A Phase 3, Randomized, Multi-Center, Open-Label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients

Project: Research project

Project Details

StatusActive
Effective start/end date2/12/25 → 2/12/28

Funding

  • Quintiles, Inc. (Prot #DB-1303-O-3002 // Prot #DB-1303-O-3002)
  • DualityBio Inc. (Prot #DB-1303-O-3002 // Prot #DB-1303-O-3002)